r926112
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2005 (NCT00115089)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Mucin-1INHIBITOR
MUC1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- r926112
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00115089 | Phase 2 | Jul 1, 2005 | Allergy and Asthma Medical Group and Research Center, San Diego, Rigel Pharmaceuticals, University of Colorado, Denver |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allergy and Asthma Medical Group and Research Center, San Diego | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Rigel Pharmaceuticals | For profit | 1 | 1 | 1 | 2005 |
| University of Colorado, Denver | Academic/Hospital | 1 | 0 | 1 | 2005 |
3 organizations
Page 1 / 1